Navigation Links
Clinical trials demonstrate benefits of instant wave-free ratio (iFR) compared to fractional flow reserve (FFR) for the assessment of coronary artery disease
Date:3/19/2017

AMSTERDAM and WASHINGTON, March 18, 2017 /PRNewswire/ -- Royal Philips (NYSE: PHG, AEX: PHIA) today announced that the results from two large clinical trials comparing patient outcomes using instant wave-free ratio (iFR) and fractional flow reserve (FFR) in the diagnosis and treatment of heart disease have been published in the New England Journal of Medicine. First released in 2013, iFR is an innovative pressure-derived index unique to Philips, a global leader in image-guided therapy solutions, allowing hyperemia-free physiological assessment of coronary blockages.

Findings from the DEFINE FLAIR and iFR Swedeheart trials, which studied 4,529 patients as part of the largest randomized coronary physiology outcome studies to date, were presented at the 2017 American College of Cardiology's Annual Scientific Session & Expo (ACC.17) in Washington, D.C., March 17–19, 2017. Investigators Dr. Justin Davies of Imperial College London in the United Kingdom, and Dr. Matthias Götberg of Lund University in Sweden, presented one-year outcome data showing that, compared to an FFR-guided strategy, an iFR-guided strategy offers a more cost-effective and faster diagnostic solution with reduced patient discomfort, while delivering consistent patient outcomes.

Continue Reading
The DEFINE FLAIR and iFR Swedeheart studies establish that iFR offers a faster procedure while almost completely eliminating severe patient symptoms as compared to FFR.
The DEFINE FLAIR and iFR Swedeheart studies establish that iFR offers a faster procedure while almost completely eliminating severe patient symptoms as compared to FFR.

"Findings from these two major clinical outcome studies have the potential to significantly improve the use of coronary physiological assessment," said Dr. Manesh Patel, MD, FACC, FSCAI, Chief of the Division of Cardiology and Co-Director of the Duke Heart Center at Duke University School of Medicine. "One of the barriers to iFR adoption has been the lack of outcome data, however now we have evidence that an iFR-guided treatment strategy is as reliable as an FFR-guided strategy with regard to future cardiovascular events. Additionally, I believe iFR will reduce patient discomfort. Together the results of these studies demonstrate large simple trials in clinical practice can be done, and should remove any barriers to the use of coronary physiology in interventional procedures."

In image-guided therapies of coronary artery disease, clinicians have been using FFR in addition to angiographic images to assess the physiology of a suspected blockage in coronary arteries to decide, guide, treat and confirm the appropriate therapy. iFR is the next generation physiologic measurement that uses the same pressure guide wires and equipment as FFR, but avoids the administration of hyperemic agents to the patient that is required with FFR.

The DEFINE FLAIR and iFR Swedeheart trials demonstrate that, compared to FFR, iFR offers reduced procedure time, cost and complexity without degradation of major adverse cardiac events (MACE). The primary endpoint of DEFINE FLAIR and iFR Swedeheart was MACE rate at one year in iFR and FFR groups. DEFINE FLAIR shows MACE rates of 6.8 percent in the iFR-guided arm versus 7.0 percent in the FFR-guided arm, p=0.003 for non-inferiority. The iFR Swedeheart outcome data showed MACE rates of 6.7 percent in the iFR-guided arm versus 6.1 percent in the FFR-guided arm, p=0.007 for non-inferiority.

The two trials further established that iFR offers a faster procedure while almost completely eliminating severe patient symptoms as compared to FFR. The DEFINE FLAIR study found that due to eliminating the need for a hyperemic drug, iFR-guided treatments lead to a 10 percent reduction in procedural time versus FFR-guided treatment (p=0.001), while reducing patient discomfort by 90 percent (p<0.01). Side effects of hyperemic drugs can include increased heart rate, pounding of the heart, flushing, elevated temperature and feelings of impending doom, which simulate physical and emotional distress.

"The clinical validation of our innovations is a critical element of our strategy in image-guided therapy," said Christopher Barys, Business Leader at Philips Volcano. "The outcomes of these clinical studies underpin the value of iFR and its benefits for patient safety and effective diagnoses. It is our hope that the results advance the adoption of iFR to help physicians improve patient care. This is one of the largest coronary physiologic datasets ever collected and truly demonstrates the value of iFR in the physiological assessment of coronary artery disease in patients."

DEFINE FLAIR was a randomized, blind comparison of clinical outcomes and cost efficiencies of iFR and FFR interventions of 2,492 patients in 49 centers across Europe, Asia, North America, and Africa. iFR Swedeheart was a randomized trial of 2,037 patients in 15 centers in Sweden, Denmark, and Iceland assessing outcomes of iFR versus FFR guided intervention. Both studies conducted their comparisons of iFR versus FFR using pressure guide wires and equipment from Philips. Since the introduction of the hyperemia-free iFR modality in 2013, iFR has been studied in nearly 15,000 patients and is used in more than 4,100 catheterization labs across the world.

For more information on Philips and the iFR data, please visit http://www.philips.com/iFR and follow the #ACC2017 conversation with @PhilipsLiveFrom throughout the event.

For further information, please contact:

Alicia Cafardi Philips Group Press Office Tel: +1 412-523-9616 Email: Alicia.Cafardi@philips.com

Kathleen Lozen Philips Volcano Tel: +1 617-529-2958 Email: Kathleen.Lozen@philips.com

About Royal Philips Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/clinical-trials-demonstrate-benefits-of-instant-wave-free-ratio-ifr-compared-to-fractional-flow-reserve-ffr-for-the-assessment-of-coronary-artery-disease-300425773.html


'/>"/>
SOURCE Royal Philips
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. Breast Cancer Index(SM) (BCI) Included in Updated Guidelines for Use of Clinical Biomarkers in Breast Cancer
2. Innovative Cardiovascular Solutions Announces Successful First Cases in European Clinical Study of EMBLOK Embolic Protection System
3. Jazz Pharmaceuticals Announces First Patient Enrolled in Phase 3 Clinical Study Evaluating JZP-258 for the Treatment of Cataplexy and Excessive Daytime Sleepiness in Narcolepsy
4. Worldwide Clinical Trials Receives 2017 CRO Leadership Awards for Outstanding Capabilities, Compatibility, Expertise, Quality and Reliability
5. Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand
6. Ortho Clinical Diagnostics Announces Expansion Of Global Agreement With Astute Medical For NephroCheck Test
7. Center Point Clinical Services Article Published in The Journal of Clinical Therapeutics
8. Astute Medical Expands Relationship With bioMérieux, Inc. And Ortho Clinical Diagnostics To Enhance NephroCheck Test Market Access
9. Boston Biomedical to Present Preclinical Data on Targeting Cancer Stemness at AACR 2017
10. Vela Genomics Launches NGS Clinical Interpretation and Reporting
11. Bellerophon Therapeutics and Worldwide Clinical Trials Selected as Finalists in 2017 Care Awards
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2017)... -- Eli Lilly and Company (NYSE: LLY ) has ... pending patent litigation in the U.S. District Court for the ... Cialis ® (tadalafil) unit dose patent. This patent was ... of the agreement, Cialis exclusivity is now expected to end ... unit dose patent for Cialis is valid and infringed by ...
(Date:7/11/2017)... 11, 2017  Sysmex America, Inc., a leading ... equipment as well as middleware information systems technology, ... make quality assurance easier and more risk free ... known for the innovation that it delivers to ... quality assurance processes to a new level with ...
(Date:7/10/2017)... July 10, 2017 The Institute for In ... is the recipient of a VITROCELL® inhalation exposure system ... Science Consortium. The device, which is designed to replace ... human lung cells to airborne test materials in an ... the VITROCELL® system for testing combustible tobacco products, as ...
Breaking Medicine Technology:
(Date:7/27/2017)... ... July 27, 2017 , ... Georgia Urology , ... Dr. Brent Sharpe who is now serving urology patients in the Braselton and ... in Flowery Branch, and is open on Mondays, Tuesdays, Wednesdays, and Fridays. The Gainesville ...
(Date:7/27/2017)... (PRWEB) , ... July 27, 2017 , ... ... a new set of teeth in a single office visit from Dr. Alejandro ... comfortable treatment solutions to his East Texas patients, including Teeth-in-a-Day® dental implants ...
(Date:7/27/2017)... Santa Clara, CA (PRWEB) , ... July 27, ... ... technology, announces the addition of a secure cloud-based polysomnography (PSG) distributed scoring solution ... to support accelerated diagnostics and sleep care management. The speed and functionality of ...
(Date:7/27/2017)... ... ... Los Angeles leg of the US movie premier of the Man in the Camo Jacket ... Clive Davis Theater inside the Grammy Museum Located in downtown Los Angeles in the LA ... rock musician, Mike Peters (of The Alarm), his rise to fame, battle with cancer and ...
(Date:7/27/2017)... ... 2017 , ... Team Novo Nordisk, the world’s first all-diabetes professional cycling team, ... a stagiaire for the remainder of the 2017 season. One of our best development ... Tour of Utah. , “Every season we are excited to move an athlete from ...
Breaking Medicine News(10 mins):